Universal flexible partnering agreement to ease drug discovery partnerships: Insilico

According to Insilico Medicine, a Maryland-based company developing artificial intelligence (AI) for drug discovery and biomarker development, partnerships between artificial intelligence (AI) companies and biotechs is often impeded by contractual issues. To develop a more flexible partnering process, Insilico Medicine recently contracted Hill Dickinson, an international commercial law firm based in the UK, to create a standardized documentation system. According to Alex Zhavoronkov, CEO of Insilico Medicine, the universal partnership agreement is intended to simplify and standardize the partnership process. Standardized documentation will be integrated into the automated partnering system already in use by Insilico and will be developed using machine learning. "To our knowledge, it is the first time in AI for drug discovery that someone developed a universal flexible partnering agreement that describes the multiple partnering options and provides the ability to structure the agreement in a semiautomatic manner," he told us.